Welcome to our dedicated page for Reviva Pharmaceuticals Holdings news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announces CEO presentation at Webull LIVE! Virtual Healthcare Investment Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, a late-stage pharmaceutical company (NASDAQ: RVPH), provided program updates on its late-stage brilaroxazine clinical program in schizophrenia, including positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data. The company also announced the initiation of registrational Phase 3 RECOVER-2 trial expected Q1 2024 and topline data from 1-year OLE trial expected Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that Dr. Laxminarayan Bhat, Founder, President, and CEO, will participate in a live 'CEO Chat' session at the Life Sciences Investor Forum on December 14th, 2023. The forum will focus on the company's late-stage therapies for CNS, inflammatory, and cardiometabolic diseases, offering investors an opportunity to engage with Dr. Bhat and John Vandermosten, Senior Biotechnology Analyst with Zacks Small-Cap Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced participation in The Benchmark Company’s Discovery One-on-One Investor Conference. Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO, will attend the event in New York, NY on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the closure of a registered direct offering, raising approximately $30,000,000 in gross proceeds. The offering involved the sale and issuance of 5,853,660 shares of common stock and warrants to purchase up to 5,853,660 shares at a combined offering price of $5.125 per share. The company plans to utilize the net proceeds for research and development activities, including the registrational Phase 3 RECOVER-2 trial, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
News
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Announces Registered Direct Offering of Common Stock and Warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported positive results from its global Phase 3 RECOVER trial for brilaroxazine in treating schizophrenia. The trial met primary and secondary endpoints, showing statistically significant and clinically meaningful symptom reductions at week 4 with 50 mg of brilaroxazine compared to placebo. The company also announced financial results for the third quarter and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. announced positive topline results from its Phase 3 RECOVER trial evaluating brilaroxazine for adults with schizophrenia. The trial met its primary endpoint, with the 50 mg dose of brilaroxazine showing a statistically significant and clinically meaningful reduction in PANSS total score compared to placebo. Brilaroxazine also demonstrated improvements in all major symptom domains and secondary endpoints. The drug was generally well-tolerated with a side effect profile comparable to placebo. Long-term data from the 1-year open-label extension trial is expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.4%
Tags
-
Rhea-AI Summary
RedChip Companies will air interviews with Sharps Technology, Inc., Reviva Pharmaceuticals Holdings, Inc., and American Resources Corp. on The RedChip Money Report, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals announces completion of Phase 3 RECOVER study for brilaroxazine in schizophrenia, topline data expected in October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
FAQ
What is the current stock price of Reviva Pharmaceuticals Holdings (RVPH)?
The current stock price of Reviva Pharmaceuticals Holdings (RVPH) is $1.24 as of November 21, 2024.
What is the market cap of Reviva Pharmaceuticals Holdings (RVPH)?
The market cap of Reviva Pharmaceuticals Holdings (RVPH) is approximately 40.5M.
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Reviva Pharmaceuticals specializes in discovering, developing, and commercializing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases.
Where is Reviva Pharmaceuticals Holdings, Inc. located?
The company is located at 5941 Optical Ct, San Jose, California, United States.
What is Brilaroxazine (RP5063)?
Brilaroxazine (RP5063) is a versatile drug candidate intended to treat multiple neuropsychiatric conditions including schizophrenia, bipolar disorder, and Parkinson's disease psychosis, among others.
What is the focus of Reviva's current pipeline?
Reviva's current pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases.
What technology does Reviva use for drug development?
Reviva Pharmaceuticals utilizes a chemical genomics-driven technology platform and proprietary chemistry for drug development.
Who can be contacted for more information about Reviva Pharmaceuticals?
For more information, you can contact Reviva Pharmaceuticals Holdings, Inc., their Investor Relations at LifeSci Advisors, or their Media Contact, Kristin Polit.
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
Another drug candidate in Reviva's pipeline is RP1208.
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
Reviva Pharmaceuticals targets therapeutic areas within the central nervous system, inflammatory, and cardiometabolic diseases.
How can I stay updated with Reviva Pharmaceuticals' latest news?
You can visit their official website or subscribe to updates through their corporate and investor relations contacts.
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
The main contact for investor inquiries is Bruce Mackle from LifeSci Advisors, LLC.
Reviva Pharmaceuticals Holdings, Inc.
Nasdaq:RVPH
RVPH Rankings
RVPH Stock Data
40.46M
28.50M
14.79%
30.07%
15.84%
Biotechnology
Pharmaceutical Preparations
United States of America
CUPERTINO